SRRK

Scholar Rock Holding

• TipRanks·1d ago

  Scholar Rock price target raised to $64 from $58 at Wedbush

• Benzinga·1d ago

  Scholar Rock Removes Catalent Indiana As Commercial Fill-Finish Facility From Its Apitegromab BLA For The Treatment Of Spinal Muscular Atrophy Under Guidance From The FDA; Now On Track To Submit Apitegromab Japanese New Drug Application By End-2026

• TipRanks·1d ago

  Scholar Rock removes Catalent Indiana from apitegromab BLA under FDA guidance

• Simply Wall St·2d ago

  Scholar Rock Holding (SRRK) After Apitegromab Progress Is The Stock Already Fully Valued

• NASDAQ·4d ago

  Scholar Rock Eyes Sept. 30 FDA Decision for SMA Drug Apitegromab

• TipRanks·5d ago

  Scholar Rock price target raised to $63 from $56 at JPMorgan

• TipRanks·5d ago

  Scholar Rock facioscapulohumeral muscular dystrophy treatment gets orphan status

• Simply Wall St·08/15 13:21

  How Investors Are Reacting To Scholar Rock (SRRK) Dual Fill-Finish Readiness Amid Ongoing FDA Review

• Simply Wall St·08/13 21:30

  Scholar Rock (SRRK) Stock Looks Priced At A Premium Today

• Dow Jones·08/13 15:19

  Scholar Rock Holding Is Maintained at Overweight by JP Morgan

• Dow Jones·08/13 15:19

  Scholar Rock Holding Price Target Raised to $63.00/Share From $56.00 by JP Morgan

• Benzinga·08/13 15:09

  JP Morgan Maintains Overweight on Scholar Rock Holding, Raises Price Target to $63

• TipRanks·08/13 12:45

  Canaccord Genuity Keeps Their Buy Rating on Scholar Rock Holding (SRRK)

• TipRanks·08/13 11:57

  J.P. Morgan Keeps Their Buy Rating on Scholar Rock Holding (SRRK)

• TipRanks·08/13 00:29

  Scholar Rock Readies for Apitegromab Launch Amid Risks